Renal Flashcards
Renal Cell Carcinoma: Epidemiology
MC primary renal malignancy
M>F
6-8th decade
Renal Cell Carcinoma: Risk Factors
SMOKING
htn obesity chronic dialysis toxic exposures heavy aspirin, acetaminophen, nsaids genetics
Renal Cell Carcinoma: Pathology
MC: clear cell papillary (chromophilic) chromophobe oncocytic collecting duct (bellini's duct) unclassified
Clear Cell RCC
deletion of chromosome 3p
proximal tubule
usually solid
Papillary RCC
proximal tubule
type 1: good prognosis
tupe 2: aggressive
Renal Cell Carcinoma: Clinical Presentation
asymptomatic until advanced disease
MC: HEMATURIA
ABDOMINAL MASS
FLANK PAIN
weight loss
L side scrotal varicocele
IVC involvement (LE edema, ascites, hepatic dysfunction, pulmonary emboli)
metastasis (lungs, lymph nodes, bone, liver, brain)
paraneoplastic syndromes
Paraneoplastic Syndromes
anemia hepatic dysfunction fever hypercalcemia cachexia erythrocytosis secondary amyloidosis thrombocytosis polymyalgia rheumatica
Renal Cell Carcinoma: Diagnostics
Preferred test:
abdominal CT with/without contrast
MRI if US or CT nondiagnostic/contraindicated
Definitive diagnosis: tissue biopsy (nephrectomy, partial nephrectomy)
Renal Cell Carcinoma: Diagnostics: evaluation of metastasis
bone scan
CT chest
MRI w/ gad
PET or PET/CT
Renal Cell Carcinoma: Treatment: stage I, II, III
surgery is curative
Renal Cell Carcinoma: Treatment: stage IV
systemic therapy
surgery
radiation
Management of a Small Renal Mass: predictors of malignancy
male sex
increasing tumor size
Management of a Small Renal Mass: <2cm
20-40% benign
<10% high-grade RCC
<1% present with/develop mets
Management of a Small Renal Mass: 4+cm
5-10% benign
20-30% high-grade or advanced RCC
Management of a Small Renal Mass: Diagnostics
1st line: renal CT
2nd line: MRI
without then with IV contrast
CMP, CBC (paraneoplastic syndrome)
renal function (CKD)
chest imaging (malignancy, mets)
biopsy
urology
Management of a Small Renal Mass: Treatment Options
surgery (partial nephrectomy)
thermal ablation (<3cm)
surveillance (<2cm)
with imaging and mets evaluation every 3-6mo for 2 years – then every 6-12mo
surveillance (<1cm)